Potential drug-like inhibitors of Group 1 influenza neuraminidase identified through computer-aided drug design

Computational Biology and Chemistry

Volumn 34, Issue 2, 2010, Pages 97-105

  Durrant, Jacob D ^a   McCammon, J Andrew ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b National Biomedical Computation Resource   (United States)

Author keywords

Drug design; Flu; H1N1; Influenza; Neuraminidase; Oseltamivir

Indexed keywords

ACTIVE SITE; COMPUTER PROGRAM; COMPUTER-AIDED DRUG DESIGN; DESIGN PROCESS; DRUG DESIGN; DRUG-RESISTANT STRAINS; IMMINENT THREATS; NEURAMINIDASE; OSELTAMIVIR; POTENTIAL DRUG; POTENTIAL INHIBITORS; PROTEIN DYNAMICS;

PROTEINS;

DESIGN;

ANTIVIRUS AGENT; ENZYME INHIBITOR; SIALIDASE;

ARTICLE; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; ENZYMOLOGY; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; MOLECULAR DYNAMICS; ANTAGONISTS AND INHIBITORS; INFLUENZA, HUMAN;

ANTIVIRAL AGENTS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MOLECULAR DYNAMICS SIMULATION; NEURAMINIDASE;

EID: 77953258396     PISSN: 14769271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.compbiolchem.2010.03.005     Document Type: Article

References (37)

1. Abdel-Ghafar A.N., Chotpitayasunondh T., Gao Z., Hayden F.G., Nguyen D.H., de Jong M.D., Naghdaliyev A., Peiris J.S., Shindo N., Soeroso S., and Uyeki T.M. Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med. 358 (2008) 261-273
2. Amaro R.E., Baron R., and McCammon J.A. An improved relaxed complex scheme for receptor flexibility in computer-aided drug design. J. Comput.-Aided Mol. Des. 22 (2008) 693-705
3. Amaro R.E., Schnaufer A., Interthal H., Hol W., Stuart K.D., and McCammon J.A. Discovery of drug-like inhibitors of an essential RNA-editing ligase in Trypanosoma brucei. Proc. Natl. Acad. Sci. 105 (2008) 17278-17283
4. Amaro R.E., Minh D.D., Cheng L.S., Lindstrom Jr. W.M., Olson A.J., Lin J.H., Li W.W., and McCammon J.A. Remarkable loop flexibility in avian influenza N1 and its implications for antiviral drug design. J. Am. Chem. Soc. 129 (2007) 7764-7765
5. Baker A.T., Varghese J.N., Laver W.G., Air G.M., and Colman P.M. Three-dimensional structure of neuraminidase of subtype N9 from an avian influenza virus. Proteins 2 (1987) 111-117
6. Beigel J.H., Farrar J., Han A.M., Hayden F.G., Hyer R., de Jong M.D., Lochindarat S., Nguyen T.K., Nguyen T.H., Tran T.H., Nicoll A., Touch S., and Yuen K.Y. Avian influenza A (H5N1) infection in humans. N. Engl. J. Med. 353 (2005) 1374-1385
7. Bohm H.-J. The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J. Comput.-Aided Mol. Des. 6 (1992) 61
8. Bohm H.J. A novel computational tool for automated structure-based drug design. J. Mol. Recogn.: JMR 6 (1993) 131
9. Bohm H.J. On the use of LUDI to search the Fine Chemicals Directory for ligands of proteins of known three-dimensional structure. J. Comput.-Aided Mol. Des. 8 (1994) 623-632
10. Bursulaya B.D., Totrov M., Abagyan R., and Brooks III C.L. Comparative study of several algorithms for flexible ligand docking. J. Comput. Aided Mol. Des. 17 (2003) 755-763
11. Cheng L.S., Amaro R.E., Xu D., Li W.W., Arzberger P.W., and McCammon J.A. Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase. J. Med. Chem. 51 (2008) 3878-3894
12. Christen M., Hunenberger P.H., Bakowies D., Baron R., Burgi R., Geerke D.P., Heinz T.N., Kastenholz M.A., Krautler V., Oostenbrink C., Peter C., Trzesniak D., and van Gunsteren W.F. The GROMOS software for biomolecular simulation: GROMOS05. J. Comput. Chem. 26 (2005) 1719-1751
13. Colman P.M. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci. 3 (1994) 1687-1696
14. Daura X., Gademann K., Jaun B., Seebach D., van Gunsteren W.F., and Mark A.E. Peptide folding: when simulation meets experiment. Angew. Chem. Int. Ed. 38 (1999) 236-240
15. Dawood F.S., Jain S., Finelli L., Shaw M.W., Lindstrom S., Garten R.J., Gubareva L.V., Xu X., Bridges C.B., and Uyeki T.M. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 360 (2009) 2605-2615
16. De Clercq E. Antiviral agents active against influenza A viruses. Nat. Rev. Drug Discov. 5 (2006) 1015-1025
17. De Clercq E., and Neyts J. Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention. Trends Pharmacol. Sci. 28 (2007) 280-285
18. de Jong M.D., Tran T.T., Truong H.K., Vo M.H., Smith G.J., Nguyen V.C., Bach V.C., Phan T.Q., Do Q.H., Guan Y., Peiris J.S., Tran T.H., and Farrar J. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353 (2005) 2667-2672
19. Durrant J.D., Amaro R.E., and McCammon J.A. AutoGrow: a novel algorithm for protein inhibitor design. Chem. Biol. Drug Des. 73 (2009) 168-178
20. Ewing T.J., Makino S., Skillman A.G., and Kuntz I.D. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J. Comput.-Aided Mol. Des. 15 (2001) 411
21. Jones G., Willett P., Glen R.C., Leach A.R., and Taylor R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267 (1997) 727
22. Kiso M., Mitamura K., Sakai-Tagawa Y., Shiraishi K., Kawakami C., Kimura K., Hayden F.G., Sugaya N., and Kawaoka Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. The Lancet 364 (2004) 759-765
23. Kobasa D., Kodihalli S., Luo M., Castrucci M.R., Donatelli I., Suzuki Y., Suzuki T., and Kawaoka Y. Amino acid residues contributing to the substrate specificity of the influenza A virus neuraminidase. J. Virol. 73 (1999) 6743-6751
24. Lin J.H., Perryman A.L., Schames J.R., and McCammon J.A. Computational drug design accommodating receptor flexibility: the relaxed complex scheme. J. Am. Chem. Soc. 124 (2002) 5632-5633
25. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46 (2001) 3-26
26. Malaisree M., Rungrotmongkol T., Decha P., Intharathep P., Aruksakunwong O., and Hannongbua S. Understanding of known drug-target interactions in the catalytic pocket of neuraminidase subtype N1. Proteins 71 (2008) 1908-1918
27. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., and Olson A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 19 (1998) 1639-1662
28. Moscona A. Oseltamivir resistance-disabling our influenza defenses. N. Engl. J. Med. 353 (2005) 2633-2636
29. Oxford J., Balasingam S., and Lambkin R. A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community. J. Antimicrob. Chemother. 53 (2004) 133-136
30. Rarey M., Kramer B., Lengauer T., and Klebe G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 261 (1996) 470
31. Rees D.C., Congreve M., Murray C.W., and Carr R. Fragment-based lead discovery. Nat. Rev. Drug Discov. 3 (2004) 660-672
32. Russell R.J., Haire L.F., Stevens D.J., Collins P.J., Lin Y.P., Blackburn G.M., Hay A.J., Gamblin S.J., and Skehel J.J. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443 (2006) 45-49
33. Schames J.R., Henchman R.H., Siegel J.S., Sotriffer C.A., Ni H., and McCammon J.A. Discovery of a novel binding trench in HIV integrase. J. Med. Chem. 47 (2004) 1879-1881
34. Varghese J.N., Laver W.G., and Colman P.M. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature 303 (1983) 35-40
35. Wishart D.S., Knox C., Guo A.C., Shrivastava S., Hassanali M., Stothard P., Chang Z., and Woolsey J. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34 (2006) D668-D672
36. Xu X., Zhu X., Dwek R.A., Stevens J., and Wilson I.A. Structural characterization of the 1918 influenza virus H1N1 neuraminidase. J. Virol. 82 (2008) 10493-10501
37. Zhang X.J., Baase W.A., and Matthews B.W. Multiple alanine replacements within alpha-helix 126-134 of T4 lysozyme have independent, additive effects on both structure and stability. Protein Sci. 1 (1992) 761-776